Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial

The goal of the present study was to evaluate a novel prospective influenza vaccination strategy for patients with plasma cell disorders. Fifty-one patients were treated with a 2-dose series of high-dose inactivated trivalent influenza vaccine. This vaccination strategy was well tolerated and led to very high rates of seroprotection against influenza.

Source: Clinical Lymphoma, Myeloma and Leukemia - March 7, 2017 Category: Hematology Authors: Andrew R. Branagan, Eamon Duffy, Randy A. Albrecht, Dennis L. Cooper, Stuart Seropian, Terri L. Parker, Geliang Gan, Fangyong Li, Daniel Zelterman, Chandra Sekhar Boddupalli, Lin Zhang, Rakesh Verma, Thomas M. Ferencz, Madhav V. Dhodapkar Tags: Original Study Source Type: research